Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 23;14(21):5200.
doi: 10.3390/cancers14215200.

Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer

Thorsten Oliver Goetze  1 , Salah-Eddin Al-Batran  1
Affiliations
Review

Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer

Thorsten Oliver Goetze et al. Cancers (Basel). .

Abstract

Gastric adenocarcinoma and esophageal cancer are the fifth and seventh most common cancer types worldwide. At the time of initial diagnosis, up to 50% of esophagogastric cancers present with distant metastatic lesions and are candidates for chemotherapy. Curative surgery in this stage is still an experimental approach. Only a small number of these metastatic patients show an oligometastatic disease with no uniform definition of what oligometastatic means in gastric cancer. Nevertheless, the question remains unanswered as to whether these patients are still candidates for curative concepts. Some studies have attempted to answer this question but have not been adequately designed to address the role of a curative-intended multimodal therapy in this setting. The current FLOT-5 is designed to potentially provide a definitive answer to the question of whether curatively intended surgery plays a role or is a disadvantage in this setting.

Keywords: Peritoneal Cancer Index; chemotherapy; gastric cancer; gastroesophageal cancer; immunotherapy; limited metastatic disease; oligometastatic disease; peritoneal carcinomatosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Useful questions to further define OMD, based, with modifications, on (Guckenberger et al., 2020) [18].
Figure 2
Figure 2
Information for decision-making used by the FLOT-5 central review expert panel.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Bernards N., Creemers G.J., Nieuwenhuijzen G.A., Bosscha K., Pruijt J.F., Lemmens V.E. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann. Oncol. 2013;24:3056–3060. doi: 10.1093/annonc/mdt401. - DOI - PubMed
    1. Wu S.G., Zhang W.W., Sun J.Y., Li F.Y., Lin Q., He Z.Y. Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer. Front. Oncol. 2018;8:302. doi: 10.3389/fonc.2018.00302. - DOI - PMC - PubMed
    1. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Participants M.T. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006;355:11–20. doi: 10.1056/NEJMoa055531. - DOI - PubMed
    1. Dresner S.M., Griffin S.M. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br. J. Surg. 2000;87:1426–1433. doi: 10.1046/j.1365-2168.2000.01541.x. - DOI - PubMed

LinkOut - more resources